Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | 0.01 | 0.15 |
| FCF Yield | -10.34% | -50.33% | -123.06% | -30.27% |
| EV / EBITDA | -7.82 | -3.60 | -14.54 | -11.08 |
| Quality | ||||
| ROIC | -152.09% | -289.63% | -52.94% | -32.13% |
| Gross Margin | 95.20% | 97.23% | 95.67% | 95.64% |
| Cash Conversion Ratio | – | 0.50 | 1.66 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.77% | -2.03% | -1.36% | -2.58% |
| Free Cash Flow Growth | 68.66% | 52.04% | -51.35% | -32.41% |
| Safety | ||||
| Net Debt / EBITDA | -4.10 | -2.16 | -11.97 | -6.74 |
| Interest Coverage | 1.38 | -2.17 | -3.02 | -2.79 |
| Efficiency | ||||
| Inventory Turnover | 0.53 | 0.21 | 0.27 | 0.28 |
| Cash Conversion Cycle | 4.40 | 283.23 | 29.37 | 65.78 |